Document |
Document Title |
WO/2022/180172A1 |
The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding...
|
WO/2022/179469A1 |
The present invention relates to a series of thienopyrimidinedione compounds and an application thereof, and specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
WO/2022/180145A2 |
The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding...
|
WO/2022/180274A1 |
The present invention relates to oxybutynin for use in the treatment of a medical condition, wherein oxybutynin is administered to the subject in need of treatment by means of a vaginal ring, that comprises a drug reservoir for the liqui...
|
WO/2022/182194A1 |
The present invention relates to a compound showing an excellent agonistic activity for a melanocortin receptor and, more specifically, to the compound of chemical formula 1, a pharmaceutical composition containing same as an active ingr...
|
WO/2022/175514A1 |
The present invention covers substituted N-(pyridin-2-yl)-acetamide compounds of general formula (I): (I) wherein X, Y, R1, R2, R3, R4, and R5 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and co...
|
WO/2022/177718A1 |
This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.
|
WO/2022/175680A1 |
The present invention relates to a composition for use in pregnant subjects comprising Lactobacillus crispatus cells, wherein said composition minimises and/or prevents pregnancy complications, such as miscarriage, preterm labour and pre...
|
WO/2022/173313A1 |
The present invention is concerned with compositions and method for use in an assisted reproduction techniques involving gestational mammals. The compositions and methods described herein involve treating (e.g.) sperm, semen, oocytes and...
|
WO/2022/173143A1 |
The present application relates to a strain of Lactobacillus reuteri, LM1071 (KCCM12650P), and to a composition for alleviating premenstrual syndrome, comprising same. According to one embodiment of the present application, the strain of...
|
WO/2022/167978A1 |
The present disclosure relates to a ready-to-use or a ready to administer parenteral dosage form of oxytocin or a pharmaceutically acceptable salt thereof comprising a ready-to-infuse, stable aqueous solution of oxytocin or a pharmaceuti...
|
WO/2022/168971A1 |
A method for controlling implantation rate in a mammal, said method comprising using at least one selected from the group consisting of: (I) a compound represented by structural formula (1); (II) a peptide comprising the amino acid seque...
|
WO/2022/166121A1 |
Novel crystal forms of Relugolix and preparation methods therefor. Specifically, three novel crystal forms APTI-I, APTI-II and APTI-III of Relugolix and preparation methods therefor are provided. The crystal forms APTI-II and APTI-III ha...
|
WO/2022/166599A1 |
A new use of PQQ and a derivative thereof. PQQ can effectively alleviate or treat primary dysmenorrhea, secondary dysmenorrhea and abnormal menstruation. After being treated with PQQ, the following effects can be achieved for patients: 1...
|
WO/2022/161416A1 |
Disclosed are an aromatic compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopic compound thereof. The compound has high P2X4 antagonistic activity, good safety, and good pharmacoki...
|
WO/2022/165017A1 |
This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.
|
WO/2022/164993A1 |
Provided are genetically edited animals, particularly dairy animals such as cows or heifers, that lactate without having first been pregnant. Also provided are methods and reagents for creating genetically modified animals. Specifically ...
|
WO/2022/162539A1 |
This invention relates to an immunogen comprising a gonadotropin releasing hormone (GnRH) peptide sequence, a kisspeptin peptide sequence and a stimulant of raising an immune response, such an immunogen for use in a method to regulate th...
|
WO/2022/157390A1 |
According to the invention there is provided an antimicrobial agent for use in maintaining or re-establishing a healthy genital microbiome, wherein the antimicrobial agent is a predatory bacterium.
|
WO/2022/156449A1 |
The present invention relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and pharmaceutically acceptab...
|
WO/2022/156193A1 |
A comprehensive antimicrobial therapy for urticaria and allergic/allergic reaction constitutions. The technical field relates to medical dermatology/allergic reaction department, traditional Chinese medicine/science of Chinese pharmacolo...
|
WO/2022/153066A1 |
A lubricant composition comprising: benzoic acid or a salt thereof in an amount of not more than 0.25% by weight; one or more monomeric polyols in a total amount of not more than 15% by weight; the composition having a pH in the range of...
|
WO/2022/150868A1 |
Nanoparticle constructs and compositions and methods thereof containing one or more peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor or a luteinizing hormone receptor), and a...
|
WO/2022/152204A1 |
Provided is a stable preparation of a human papillomavirus virus-like particle vaccine. The stable preparation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and ...
|
WO/2022/155341A1 |
The present disclosure relates to a formulations and methods for transdermal delivery of a phosphodiesterase-5 (PDE5) inhibitor through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a ...
|
WO/2022/150869A1 |
Nanoparticle constructs and compositions and methods thereof containing one or more peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor or a luteinizing hormone receptor), and a...
|
WO/2022/150878A1 |
Peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor, a luteinizing hormone receptor, or an Anti-Mullerian hormone receptor) are described herein. In addition, nanoparticle const...
|
WO/2022/148699A1 |
The present invention relates to a composition comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus gasseri LB905R deposited under accession number DSM 34094, Lactobacillus crispatus LB...
|
WO/2022/148138A1 |
Lactobacillus crispatus Lc31 and Lc83 capable of preventing and/or treating cervical squamous carcinoma. The preservation number of the Lactobacillus crispatus Lc31 is CGMCC No. 21348, and the preservation number of the Lactobacillus cri...
|
WO/2022/147925A1 |
A patch for treating male erectile dysfunction and a preparation method therefor. The patch comprises the following active ingredients: an alcohol extract of Li medicine spider, water extracts of Alismatis rhizoma, Poria, Schisandra chin...
|
WO/2022/148792A1 |
The invention relates to a method for treating endometriosis, by administering DNase I, and, in particular, for treating a patient with a cell-free DNA level above normal, a fortiori if this cell-free DNA has a methylation profile typica...
|
WO/2022/142150A1 |
A clindamycin phosphate vaginal tablet, which is prepared from the following raw materials in parts by weight: 125 parts of clindamycin phosphate, 140-160 parts of lactose, 90-95 parts of microcrystalline cellulose, 7-8 parts of sodium s...
|
WO/2022/146061A1 |
Provided is a pharmaceutical composition comprising as active ingredients: 5mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution r...
|
WO/2022/142385A1 |
The present invention provides a method for refining dienogest. The method is a recrystallization method. The present invention belongs to the technical field of medicine synthesis. The refining of dienogest comprises the following steps...
|
WO/2022/143489A1 |
A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxi...
|
WO/2022/141441A1 |
Provided is a follicle-stimulating hormone (FSH). The preparation thereof comprises the following steps: introducing a secretion signal peptide into the two subunits FSHα and FSHβ of the FSH, and then individually expressing same, foll...
|
WO/2022/139443A1 |
The present invention relates to crystalline form I of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form I of the compound represented by chemica...
|
WO/2022/135545A1 |
Provided is use of a cell-free fat extract for preparing a composition or a formulation. The composition or formulation is used for (i) preventing and/or treating erectile dysfunction; and/or (ii) preventing and/or treating corpus cavern...
|
WO/2022/139441A1 |
The present invention relates to an amorphous compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The amorphous compound represented by chemical formula 1 of the pres...
|
WO/2022/139444A1 |
The present invention relates to a crystal type II of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystal type II of the compound represented by chemica...
|
WO/2022/139477A1 |
The present invention provides a medicinal and/or culinary use of an Artemisia annua extract for treating, ameliorating and/or preventing at least one selected from among bone diseases, menopausal disorders, cardiovascular diseases, neur...
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
WO/2022/140417A1 |
The present disclosure provides a method of treating a sexual dysfunction in a human male subject in need thereof comprising administering an effective amount of a mesembrine alkaloid or salt thereof to the subject in need thereof. Also ...
|
WO/2022/139406A1 |
The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
WO/2022/138909A1 |
[Problem] The present invention provides: an equol clathrate having improved solubility in water; an equol-absorbent composition containing the equol clathrate; a production method for the clathrate; and an equol-absorbent composition co...
|
WO/2022/139446A1 |
The present invention relates to a crystalline form III of a compound represented by chemical formula 1, a preparation method therefor, and a pharmaceutical composition comprising same. The crystalline form III of the compound represente...
|
WO/2022/126179A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to modulate the activity of oxytoci...
|
WO/2022/129484A1 |
The present invention relates to a composition for use in the treatment of infertility. The composition of the invention finds utility as a personal lubricant that can be used to increase sperm motility or sperm velocity. Also disclosed ...
|
WO/2022/124494A1 |
A pharmaceutical composition according to the present invention comprises a first liquid containing PEG-VS and a second liquid containing a crosslinker inclusive of an amino acid sequence cleaved by a proteinase, wherein the first liquid...
|